• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glooko inks partnership with insulin dosing software developer Hedia

April 14, 2023 By Sean Whooley

Glooko Hedia partnershipGlooko announced that it entered into a global partnership with Hedia to integrate its technology into Glooko’s diabetes management platforms.

The companies aim to provide an interoperable solution that brings together connected care, remote patient monitoring and digital therapeutics. This combination could enhance access for those with type 1 and type 2 diabetes requiring bolus insulin dosing advice.

Palo Alto, California-based Glooko’s current platforms enable patients to share diabetes data with healthcare providers. That includes blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight.

By integrating the Hedia Diabetes Assistant, users can receive bolus insulin dosing advice. That enables personalized care, reducing the burden of manually calculating required doses. When used with connected insulin pens, this combination brings enhanced visibility for providers managing patients on multiple daily injection therapy.

“The robust clinical data supporting Hedia’s efficacy demonstrates this could be a viable alternative for patients who are not able to access insulin pumps,” said Glooko CEO Russ Johannesson. “This partnership shows how interoperability gives people with diabetes the optimal tools available to ease the management of their condition and enhance health outcomes such as the stability of blood glucose levels.”

Glooko said in a news release that the integration improves its remote patient monitoring and supports virtual consultations.

The companies plan to initially launch their integration in Europe in the fourth quarter of 2023 and the first quarter of 2024.

“Glooko has demonstrated their strength in these areas with multiple third-party certifications, and that’s a key driver behind our partnership,” added Hedia CEO Peter Lucas. “Hedia’s Class IIb medical device designation ensures that the best solutions are being provided to patients and their care teams.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: glooko, Hedia

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS